Join
Live feed
·
INSIDERFilingvia Quantisnow
Lexeo Therapeutics Inc. logo

Chief Development Officer See Tai Sandi was granted 38,750 shares, increasing direct ownership by 233% to 55,375 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
LXEO· Lexeo Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LXEO (Lexeo Therapeutics Inc.) and more on Quantisnow.